Literature DB >> 19136928

Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.

Zhi Rong Qian1, Sylvia L Asa, Haruhiko Siomi, Mikiko C Siomi, Katsuhiko Yoshimoto, Shozo Yamada, Elaine Lu Wang, Md Mustafizur Rahman, Hiroshi Inoue, Mitsuo Itakura, Eiji Kudo, Toshiaki Sano.   

Abstract

High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors. Recent studies report that high-mobility group A2 is negatively regulated by the let-7 microRNAs (miRNAs) family in vitro. The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis. However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas. Using immunohistochemistry, we analyzed high-mobility group A2 expression with respect to various clinicopathologic factors in 98 pituitary adenomas. Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas. High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05). High levels of high-mobility group A2 expression were more frequently observed in macroadenomas than in microadenomas (P<0.05). High levels of high-mobility group A2 expression also significantly correlated with the proliferation marker Ki-67 (P<0.0001). Real-time quantitative RT-PCR analysis was carried out to evaluate the expression of let-7 in 55 pituitary adenomas. Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05). An inverse correlation between let-7 and high-mobility group A2 expression was evident (R=-0.33, P<0.05). These findings support a causal link between let-7 and high-mobility group A2 whereby loss of let-7 expression induces high-mobility group A2 upregulation that represents an important mechanism in pituitary tumorigenesis and progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19136928     DOI: 10.1038/modpathol.2008.202

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  39 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  MicroRNAs in the human pituitary.

Authors:  Milani Sivapragasam; Fabio Rotondo; Ricardo V Lloyd; Bernd W Scheithauer; Michael Cusimano; Luis V Syro; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

Review 3.  The pseudocapsule surrounding a pituitary adenoma and its clinical significance.

Authors:  Xin Qu; Guangming Xu; Yuanming Qu; Tao Song
Journal:  J Neurooncol       Date:  2010-06-06       Impact factor: 4.130

Review 4.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

5.  MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα.

Authors:  Yuanchuan Wang; Xiaohong Yin; Long Zhao; Shun Li; Jie Duan; Renzhao Kuang; Junwei Duan
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

6.  Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.

Authors:  Stanley B DeVore; Coleman H Young; Guangyuan Li; Anitha Sundararajan; Thiruvarangan Ramaraj; Joann Mudge; Faye Schilkey; Aaron Muth; Paul R Thompson; Brian D Cherrington
Journal:  Mol Cell Biol       Date:  2018-09-14       Impact factor: 4.272

Review 7.  MicroRNAs: Suggested role in pituitary adenoma pathogenesis.

Authors:  M R Gadelha; L Kasuki; J Dénes; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2013-11       Impact factor: 4.256

8.  Testis-specific miRNA-469 up-regulated in gonadotropin-regulated testicular RNA helicase (GRTH/DDX25)-null mice silences transition protein 2 and protamine 2 messages at sites within coding region: implications of its role in germ cell development.

Authors:  Lisheng Dai; Chon-Hwa Tsai-Morris; Hisashi Sato; Joaquin Villar; Jung-Hoon Kang; Jiabao Zhang; Maria L Dufau
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

Review 9.  MiRNA as potential biomarkers and therapeutic targets for gastric cancer.

Authors:  Vivian Yvonne Shin; Kent-Man Chu
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

10.  HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Authors:  Monica Fedele; Orlando Paciello; Davide De Biase; Mario Monaco; Gennaro Chiappetta; Michela Vitiello; Antonio Barbieri; Domenica Rea; Antonio Luciano; Serenella Papparella; Claudio Arra; Alfredo Fusco
Journal:  Cell Cycle       Date:  2018-01-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.